Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience
CONCLUSION: Peripheral venous access is feasible for autologous PBSC collection in more than a half of patients, in particular in those with multiple myeloma. Changes in the treatment of multiple myeloma, using new proteasome inhibitors-based and immunomodulatory agents that do not adversely affect peripheral veins, have enabled the use of PVA even at the high blood flow rates required by LVL. Peripheral venous access is not associated with safety issues or with a lesser collection efficiency, and it is cost-effective as well. Each patient referred to autologous PBSC collection needs to be evaluated individually by the exp...
Source: Clinical Lymphoma and Myeloma - November 9, 2023 Category: Cancer & Oncology Authors: Ines Bojani ć Greta Novosel Marijana Luka č Baričević Petar Škrnjug Elena Horvat Sanja Mazi ć Josip Batini ć Sandra Ba šić Kinda Branka Golubi ć Ćepulić Source Type: research
Vascular access for autologous peripheral blood stem cells collection by large volume leukapheresis: Single center experience
CONCLUSION: Peripheral venous access is feasible for autologous PBSC collection in more than a half of patients, in particular in those with multiple myeloma. Changes in the treatment of multiple myeloma, using new proteasome inhibitors-based and immunomodulatory agents that do not adversely affect peripheral veins, have enabled the use of PVA even at the high blood flow rates required by LVL. Peripheral venous access is not associated with safety issues or with a lesser collection efficiency, and it is cost-effective as well. Each patient referred to autologous PBSC collection needs to be evaluated individually by the exp...
Source: Clinical Lymphoma and Myeloma - November 9, 2023 Category: Cancer & Oncology Authors: Ines Bojani ć Greta Novosel Marijana Luka č Baričević Petar Škrnjug Elena Horvat Sanja Mazi ć Josip Batini ć Sandra Ba šić Kinda Branka Golubi ć Ćepulić Source Type: research
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
CONCLUSION: PR-CHOP has led to durable responses in most patients, with the best outcomes in PD-L1-expressing disease. Furthermore, the safety profile was manageable, with no consistent pattern of late events. These data support ongoing strategies incorporating ICIs in frontline DLBCL therapy and confirmation of predictive biomarkers including tumor PD-L1 expression.PMID:37926672 | DOI:10.1016/j.clml.2023.10.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 5, 2023 Category: Cancer & Oncology Authors: Carrie Ho Ajay K Gopal Brian G Till Mazyar Shadman Ryan C Lynch Andrew J Cowan Qian V Wu Jenna Voutsinas Heather A Rasmussen Katherine Blue Chaitra S Ujjani Ryan D Cassaday Jonathan R Fromm Min Fang Stephen D Smith Source Type: research
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
CONCLUSION: PR-CHOP has led to durable responses in most patients, with the best outcomes in PD-L1-expressing disease. Furthermore, the safety profile was manageable, with no consistent pattern of late events. These data support ongoing strategies incorporating ICIs in frontline DLBCL therapy and confirmation of predictive biomarkers including tumor PD-L1 expression.PMID:37926672 | DOI:10.1016/j.clml.2023.10.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 5, 2023 Category: Cancer & Oncology Authors: Carrie Ho Ajay K Gopal Brian G Till Mazyar Shadman Ryan C Lynch Andrew J Cowan Qian V Wu Jenna Voutsinas Heather A Rasmussen Katherine Blue Chaitra S Ujjani Ryan D Cassaday Jonathan R Fromm Min Fang Stephen D Smith Source Type: research
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
CONCLUSION: PR-CHOP has led to durable responses in most patients, with the best outcomes in PD-L1-expressing disease. Furthermore, the safety profile was manageable, with no consistent pattern of late events. These data support ongoing strategies incorporating ICIs in frontline DLBCL therapy and confirmation of predictive biomarkers including tumor PD-L1 expression.PMID:37926672 | DOI:10.1016/j.clml.2023.10.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 5, 2023 Category: Cancer & Oncology Authors: Carrie Ho Ajay K Gopal Brian G Till Mazyar Shadman Ryan C Lynch Andrew J Cowan Qian V Wu Jenna Voutsinas Heather A Rasmussen Katherine Blue Chaitra S Ujjani Ryan D Cassaday Jonathan R Fromm Min Fang Stephen D Smith Source Type: research
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up
CONCLUSION: PR-CHOP has led to durable responses in most patients, with the best outcomes in PD-L1-expressing disease. Furthermore, the safety profile was manageable, with no consistent pattern of late events. These data support ongoing strategies incorporating ICIs in frontline DLBCL therapy and confirmation of predictive biomarkers including tumor PD-L1 expression.PMID:37926672 | DOI:10.1016/j.clml.2023.10.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 5, 2023 Category: Cancer & Oncology Authors: Carrie Ho Ajay K Gopal Brian G Till Mazyar Shadman Ryan C Lynch Andrew J Cowan Qian V Wu Jenna Voutsinas Heather A Rasmussen Katherine Blue Chaitra S Ujjani Ryan D Cassaday Jonathan R Fromm Min Fang Stephen D Smith Source Type: research
Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)
Mol Clin Oncol. 2023 Oct 12;19(6):95. doi: 10.3892/mco.2023.2691. eCollection 2023 Dec.ABSTRACTImmunotherapy has emerged as a crucial treatment option, particularly for types of cancer that display resistance to conventional therapies. A remarkable breakthrough in this field is the development of chimeric antigen receptor (CAR) T cell therapy. CAR T cells are generated by engineering the T cells of a patient to express receptors that can recognize specific tumor antigens. This groundbreaking approach has demonstrated impressive outcomes in hematologic malignancies, including diffuse large B cell lymphoma, B cell acute lymp...
Source: Clinical Lymphoma and Myeloma - November 3, 2023 Category: Cancer & Oncology Authors: Rayansh Poojary Andy Fang Song Benny Shone Song Carly Shaw Song Liqing Wang Jianxun Song Source Type: research
Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities
Clin Lymphoma Myeloma Leuk. 2023 Oct 10:S2152-2650(23)02132-8. doi: 10.1016/j.clml.2023.09.009. Online ahead of print.ABSTRACTMultiple myeloma (MM) accounts for 10% of hematologic cancers in the U.S.; however, incidence and mortality occur disproportionately between racial groups in real-world settings. Our study's objective was to systematically characterize the disparities in overall survival (OS) among Black and White patients with MM in the US using real-world evidence studies. A systematic literature review was undertaken by searching Embase and MEDLINE for observational studies conducted in the US, published between ...
Source: Clinical Lymphoma and Myeloma - November 3, 2023 Category: Cancer & Oncology Authors: Joseph Mikhael Allie Cichewicz Elizabeth S Mearns Allicia Girvan Vicki Pierre Neda Al Rawashdh Archibong Yellow-Duke R Frank Cornell Michael Nixon Source Type: research
Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)
Mol Clin Oncol. 2023 Oct 12;19(6):95. doi: 10.3892/mco.2023.2691. eCollection 2023 Dec.ABSTRACTImmunotherapy has emerged as a crucial treatment option, particularly for types of cancer that display resistance to conventional therapies. A remarkable breakthrough in this field is the development of chimeric antigen receptor (CAR) T cell therapy. CAR T cells are generated by engineering the T cells of a patient to express receptors that can recognize specific tumor antigens. This groundbreaking approach has demonstrated impressive outcomes in hematologic malignancies, including diffuse large B cell lymphoma, B cell acute lymp...
Source: Clinical Lymphoma and Myeloma - November 3, 2023 Category: Cancer & Oncology Authors: Rayansh Poojary Andy Fang Song Benny Shone Song Carly Shaw Song Liqing Wang Jianxun Song Source Type: research
Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)
Mol Clin Oncol. 2023 Oct 12;19(6):95. doi: 10.3892/mco.2023.2691. eCollection 2023 Dec.ABSTRACTImmunotherapy has emerged as a crucial treatment option, particularly for types of cancer that display resistance to conventional therapies. A remarkable breakthrough in this field is the development of chimeric antigen receptor (CAR) T cell therapy. CAR T cells are generated by engineering the T cells of a patient to express receptors that can recognize specific tumor antigens. This groundbreaking approach has demonstrated impressive outcomes in hematologic malignancies, including diffuse large B cell lymphoma, B cell acute lymp...
Source: Clinical Lymphoma and Myeloma - November 3, 2023 Category: Cancer & Oncology Authors: Rayansh Poojary Andy Fang Song Benny Shone Song Carly Shaw Song Liqing Wang Jianxun Song Source Type: research
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States
CONCLUSION: These real-world outcomes are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. OST in patients with CTCL previously treated with ≥1 systemic therapy.PMID:37919137 | DOI:10.1016/j.clml.2023.10.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 2, 2023 Category: Cancer & Oncology Authors: Stefan K Barta Nicholas Liu Maral DerSarkissian Rose Chang Mingchen Ye Mei Sheng Duh Andy Surinach Michelle Fanale Kristina S Yu Source Type: research
Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
Hematological involvement in sarcoidosis: from cytopenias to lymphoma
We present an updated overview of the hematological involvementassociated with sarcoidosis, including a management approach forcytopenias and revisiting the association with hematologicalmalignancies.AREAS COVERED: Theetiology of cytopenias in sarcoidosis can be attributed to two majoretiopathogenic mechanisms: infiltration of hematopoietic organs suchas the spleen and bone marrow, and autoimmune-mediated cytopenias.With respect to the association with hematological malignancies, itrequires careful evaluation of patients from a chronologicalperspective. Patients must be classified into one of three pathogenicscenarios, inc...
Source: Clinical Lymphoma and Myeloma - October 25, 2023 Category: Cancer & Oncology Authors: Pilar Brito-Zer ón Elyse E Lower Manuel Ramos-Casals Robert P Baughman Source Type: research
